Updates

These updates includes material published by third parties and compiled by PAHO. PAHO has taken reasonable precautions to verify the information contained in the document. However, this material is being distributed without warranty of any kind. The reader is responsible for the interpretation and use of this information and in no event shall PAHO be held liable for any damages arising from its use.
  • Updates
  • Official reports from pharmacovigilance programs
  • Clarifications/conclusions of events presented in previous communications
  • Other related updates
08/13/2021

Brazil

Read more
07/19/2021

Brazil

Read more
04/27/2021

GACVS: Review of rare adverse blood clotting events with AstraZeneca COVID-19 vaccine (Vaxzevria and Covishield)

On 16 April 2021, the World Health Organization (WHO) published conclusions from the Global Advisory Committee on Vaccine Safety (GACVS) review of the latest evidence related to reports of rare adverse events following immunization with the AstraZeneca COVID-19 vaccine (Vaxzevria and Covishield).

Read more
04/27/2021

Updated WHO Interim recommendations for use of the COVID-19 ChAdOx1-S [recombinant] vaccine (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, and SK Bioscience)

On 21 April 2021, the World Health Organization (WHO) published an update to the document “Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience),” based on the recommendations issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 8 February 2021 (1), updated on 21 April 2021.

Read more
04/19/2021

Review of rare blood-clotting adverse events with the AstraZeneca COVID-19 vaccine (Vaxzevria and Covishield)

by the World Health Organization's Global Advisory Committee on Vaccine Safety

Read more
04/11/2021

The number of reported cases of venous thromboembolism associated with the Oxford- AstraZeneca vaccine in Denmark is lower than the expected number of cases in the population

An electronic population study of Denmark's hospital patient registry (Danish National Patient Registry, or DNPR) of 4.9 million adults estimated the number of thromboembolic events and the incidence of such events in the Danish population between 2010 and November 2018.

Read more
04/11/2021

ANVISA requests modification of Oxford-AstraZeneca-Fiocruz vaccine package insert

On Wednesday, 4 April 2021, ANVISA reported that it had requested modification of the insert for the Oxford- AstraZeneca-Fiocruz vaccine, to include in the warnings and precautions section the possibility of very rare cases of blood clots associated with thrombocytopenia.

Read more
03/31/2021

Possible explanation of rare prothrombotic events with the AstraZeneca vaccine in Europe

There are press releases and communiqués, though no published studies, stating the following: In response to reports that emerged after a few recipients of the AstraZeneca COVID-19 vaccine...

Read more
03/31/2021

GACVS statement on rare thrombotic events with the AstraZeneca vaccine in Europe

The COVID-19 subcommittee of the Global Advisory Committee on Vaccine Safety (GACVS) met in March 2021 to review available data on cases of thromboembolism and thrombocytopenia reported following administration of the AstraZeneca COVID-19 vaccine.

Read more